Ubhe Anand
AbbVie, Irvine, CA, USA.
Inflamm Res. 2024 Dec;73(12):2231-2247. doi: 10.1007/s00011-024-01960-y. Epub 2024 Oct 26.
This article is aims to provide an overview of studies reported in the literature to investigate the etiological role of IL-1/IL-1ra in various disease conditions and the different drug delivery systems developed to achieve IL-1ra as a possible therapeutic option.
Studies reported in PubMed, Google scholar, and other open-source literature related to etiological involvement of IL-1ra in pathophysiological conditions and various drug delivery schemes developed for IL-1ra for its efficacy evaluation as a possible treatment for different disease conditions were surveyed.
The pathophysiological conditions involving IL-1/IL-1 ra spanned CNS-related disorders, Diabetes, Cardiac disorders, Ocular disease conditions, Gastrointestinal conditions, Tumor growth & metastasis, and miscellaneous conditions. The drug delivery systems developed for IL-1ra included a commercial drug product, Gene therapy, Antibody fusions, Extended-release delivery systems, and Pegylated-IL-1ra systems.
本文旨在概述文献中报道的研究，以探讨白细胞介素-1/白细胞介素-1受体拮抗剂（IL-1/IL-1ra）在各种疾病状态下的病因学作用，以及为将IL-1ra作为一种可能的治疗选择而开发的不同药物递送系统。
对PubMed、谷歌学术及其他开源文献中报道的有关IL-1ra在病理生理状况下的病因学参与情况以及为评估IL-1ra作为不同疾病状态的可能治疗方法的疗效而开发的各种药物递送方案的研究进行了调查。
涉及IL-1/IL-1ra的病理生理状况包括中枢神经系统相关疾病、糖尿病、心脏疾病、眼部疾病、胃肠道疾病、肿瘤生长与转移以及其他各种状况。为IL-1ra开发的药物递送系统包括一种商业药物产品、基因治疗、抗体融合物、缓释递送系统以及聚乙二醇化IL-1ra系统。
